IMRICOR'S U.S. COMMERCIAL MOMENTUM ACCELERATES

CHILDREN'S MEDICAL CENTER DALLAS TO BECOME SECOND U.S. CUSTOMER

Key Highlights

- **Children's Medical Center Dallas is purchasing Imricor's NorthStar®** iMR mapping and guidance system, becoming the **second commercial U.S. hospital customer** just two weeks after the launch of Imricor's U.S. commercial operations
- Children's Medical Center Dallas is the **flagship hospital of Children's Health℠**, one of the largest pediatric health care providers in the United States, caring for children through **more than one million patient visits annually** across its system
- Since 1961, Children's Medical Center Dallas has been the **primary pediatric clinical partner of UT Southwestern Medical Center**, one of the nation's leading medical education and biomedical research institutions
- The hospital has an **existing, fully operational Philips iMR lab**, meaning no lab construction is required and NorthStar-guided procedures can commence rapidly following installation
- Children's Medical Center Dallas' adoption of NorthStar is the **first tangible commercial outcome of the Philips Declaration of Compatibility** announced last week, which immediately expanded Imricor's addressable installed base for NorthStar to the two leading MRI vendors: Siemens at Rady Children's – San Diego and Philips at Children's Medical Center Dallas
- Children's Medical Center Dallas will launch a NorthStar-guided iMR **cardiac catheterisation** program, delivering **100% radiation-free procedures** for children with congenital heart disease
- Children's Medical Center Dallas will be the second customer under **Imricor Cardiovascular**, validating the newly launched vertical and the market opportunity across more than **250 children's hospitals** and more than **2,000 adult hospitals** in the United States
- Several additional U.S. hospitals remain in the **final stages of the purchasing process**, with additional NorthStar customers expected over the coming weeks
- These advanced sales discussions are **not only limited** to Children's hospitals validating the broad appeal of Imricor's globally unique technology platform

10 August 2026 – Melbourne, Australia (**9 August 2026** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc.** (**Company** or **Imricor**) (**ASX: IMR**) is pleased to announce that Children's Medical Center Dallas will become the Company's second U.S. customer, adopting Imricor's NorthStar interventional magnetic resonance (iMR) mapping and guidance system. Coming just two weeks after announcing Rady Children's Hospital–San Diego as Imricor's first U.S. customer, today's announcement confirms the commercial momentum building behind

Imricor's U.S. launch and the Imricor Cardiovascular vertical. NorthStar will be deployed in the hospital's existing, fully operational Philips iMR lab.

First Philips Lab – Compatibility Delivering Pipeline

Today's announcement carries particular strategic significance as the first commercial outcome of the Philips Third Party Declaration of Compatibility with Imricor announced last week. Children's Medical Center Dallas operates a Philips MRI scanner in its iMR lab, while Rady Children's operates a Siemens system. Within two weeks of launching U.S. commercial operations, Imricor's first two U.S. customers span each of the two leading MRI vendor platforms, tangible evidence that the Philips compatibility declaration has immediately expanded the Company's addressable installed base and unlocked a substantial portion of the U.S. hospital pipeline that was previously inaccessible.

Importantly, the iMR lab at Children's Medical Center Dallas is already built and fully operational. With no lab construction required, the pathway to first procedures is significantly shortened: once NorthStar is installed, the hospital can rapidly commence its NorthStar-guided iMR cardiac catheterisation program, offering children with congenital heart disease procedures that are 100% radiation-free. For these patients, who may require repeated catheterisations from the earliest years of life, eliminating exposure to ionising X-ray radiation is a significant clinical benefit, delivered alongside the superior soft tissue visualisation and richer functional data that MR guidance provides.

Children's Medical Center Dallas will be the second customer under Imricor Cardiovascular, the vertical launched two weeks ago that harnesses the power of magnetic resonance to help physicians perform cardiac catheterisation procedures under real-time MR guidance. With two of the nation's leading children's hospitals now committed to iMR programs, the Company's thesis is being rapidly validated in the market.

Commercial momentum continues to build. Several additional children's and adult U.S. hospitals remain in the final stages of their purchasing processes, and additional NorthStar customers are expected over the coming weeks.

About Children's Medical Center Dallas

Children's Medical Center Dallas is one of the most respected pediatric hospitals in the United States. The flagship hospital of Children's Health, and one of the largest pediatric health care providers in the country, it is licensed for 488 beds and anchors a system that cares for children through more than one million patient visits each year, drawing patients from all 50 states and around the world. In the U.S. News & World Report 2025–2026 Best Children's Hospitals report, Children's Medical Center Dallas is ranked No. 9 in the nation for Pediatric Cardiology & Heart Surgery and is nationally ranked in all 11 pediatric specialties, a distinction it has earned for eight consecutive years and one held by only a select few hospitals nationwide.

The hospital is also home to one of the country's premier academic pediatric heart programs. Since 1961, Children's Medical Center Dallas has been the primary pediatric clinical partner of UT Southwestern Medical Center, one of the nation's leading medical education and biomedical research institutions. The physicians at the Heart Center of Children's Medical Center Dallas have been at the forefront of cardiac magnetic resonance research for many years, making the program a natural early adopter of NorthStar and a powerful clinical partner as Imricor advances the field of interventional MR.

> *"Interventional MR has been a cornerstone of our Heart Center's innovation strategy. Working with Imricor allows our team to continue setting the pace for how congenital heart disease is treated in children and adults in the future."*
>
> **— Professor Gerald Greil, MD, PhD,** Chief of Cardiology and the Pogue Family Distinguished Chair in Pediatric Cardiology at UT Southwestern Medical Center
>
> *"The field of interventional MR is important for our patients, but it has not progressed as quickly as we would have liked. Our use of NorthStar and our partnership with Imricor is going to swiftly advance the field. We are excited to see Imricor moving iMR forward and delivering clinical products to market."*
>
> **— Professor Suren Reddy, MD,** Professor of Pediatrics and head of UT Southwestern's Cardiac Catheterization Laboratory
>
> *"This collaboration underscores that advanced cardiac MR is not just a diagnostic tool. It is becoming central to how we perform interventions. That is an exciting step forward for our patients and for the field."*
>
> **— Professor Mohammad Tarique Hussain, MD, PhD**, Professor of Pediatric Cardiology and Radiology and Director of Advanced Imaging (MRI and CT), Department of Pediatrics, UT Southwestern Medical Center

Imricor's Chair and CEO, Steve Wedan, said: "Two weeks ago we launched our U.S. commercial operations, and today one of the most decorated pediatric heart programs in the country has chosen to build its interventional MR future with Imricor. Children's Medical Center Dallas and UT Southwestern have been pioneers in cardiac MR for decades, and their decision to adopt NorthStar is a powerful endorsement of our technology and our vision for radiation-free interventional care.

"Today also shows exactly why the Philips Declaration of Compatibility we announced last week matters. Just days later, NorthStar is headed into an existing Philips iMR lab. With our first two U.S. customers running Siemens and Philips systems respectively, NorthStar now spans the two leading MRI platforms, and the addressable pipeline in front of us has expanded accordingly. Because the iMR lab in Dallas is already built and operational, patients will benefit quickly. This is what the beginning of a new standard of care looks like."

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO imricor

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance (MR) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MR's superior imaging capabilities.

Imricor's Products

Imricor is a pioneer and world leader in developing MR-compatible products for interventional MR (iMR) procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used in an iMR lab.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. NorthStar and Vision-MR Diagnostic Catheter are cleared in the US.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons excluding qualified institutional buyers (QIBs, as defined in Rule 144A under the Securities Act). However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.